Clinical Trial Update: A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing Fabrazyme (agalsidase beta) to placebo in patients with advanced Fabry disease completed; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Phase 4 | Status: COMPLETED | Results posted: 2010-12-15